DE60237449D1 - Ammensetzungen und damit in beziehung stehende verwendungen - Google Patents

Ammensetzungen und damit in beziehung stehende verwendungen

Info

Publication number
DE60237449D1
DE60237449D1 DE60237449T DE60237449T DE60237449D1 DE 60237449 D1 DE60237449 D1 DE 60237449D1 DE 60237449 T DE60237449 T DE 60237449T DE 60237449 T DE60237449 T DE 60237449T DE 60237449 D1 DE60237449 D1 DE 60237449D1
Authority
DE
Germany
Prior art keywords
polymers
compositions
amments
related uses
nanospheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237449T
Other languages
German (de)
English (en)
Inventor
Justin Hanes
Jie Fu
Jennifer Fiegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE60237449D1 publication Critical patent/DE60237449D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)
DE60237449T 2001-06-22 2002-06-21 Ammensetzungen und damit in beziehung stehende verwendungen Expired - Lifetime DE60237449D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29972901P 2001-06-22 2001-06-22
PCT/US2002/019772 WO2003000237A2 (en) 2001-06-22 2002-06-21 Biodegradable polymer coompositions

Publications (1)

Publication Number Publication Date
DE60237449D1 true DE60237449D1 (de) 2010-10-07

Family

ID=23156038

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237449T Expired - Lifetime DE60237449D1 (de) 2001-06-22 2002-06-21 Ammensetzungen und damit in beziehung stehende verwendungen

Country Status (7)

Country Link
US (1) US7163697B2 (enExample)
EP (1) EP1406593B1 (enExample)
JP (1) JP4758607B2 (enExample)
AT (1) ATE478656T1 (enExample)
AU (1) AU2002322289A1 (enExample)
DE (1) DE60237449D1 (enExample)
WO (1) WO2003000237A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466039A1 (en) * 2001-11-23 2003-06-05 Rutgers, The State University Improved synthesis of polyanhydrides
US7351749B2 (en) * 2002-12-16 2008-04-01 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Process for manufacture of personal care products utilizing a concentrate water phase
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
EP1686963A1 (en) * 2003-10-27 2006-08-09 PSivida Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
JP2005206491A (ja) * 2004-01-21 2005-08-04 Medgel Corp 肺気腫を治療するための経肺投与用製剤
EP1713514B1 (en) * 2004-01-28 2021-11-24 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
CA2590098C (en) * 2004-12-10 2015-03-31 Justin Hanes Functionalized poly (ether-anhydride) block copolymers
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
FR2887886B1 (fr) † 2005-07-01 2010-01-08 Oreal Polymere cationique neutralise, composition le comprenant et procede de traitement cosmetique
US20070225472A1 (en) * 2006-03-23 2007-09-27 Varshney Sunil K Polyanhydride polymers and their uses in biomedical devices
CA2648291A1 (en) * 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
US20080014170A1 (en) * 2006-07-14 2008-01-17 Olexander Hnojewyj Drug delivery polyanhydride composition and method
ITMI20061539A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
US20090169628A1 (en) 2006-10-17 2009-07-02 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
NO20065147L (no) * 2006-11-08 2008-05-09 Ntnu Tech Transfer As Nanokompositter basert på cellulosewhiskers og celluloseplast
JP5578655B2 (ja) 2007-03-02 2014-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 微粒子による薬物送達
US8623397B2 (en) * 2007-04-13 2014-01-07 The Regents Of The University Of Michigan Delivery device and method for forming the same
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
US20080311172A1 (en) * 2007-04-25 2008-12-18 Schapira Jay N Programmed-release, nanostructured biological construct
CA2708514A1 (en) * 2007-12-31 2009-07-16 Armark Authentication Technologies, Llc Article and method for focused delivery of therapeutic and/or diagnostic materials
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2315571A4 (en) * 2008-07-16 2013-05-01 Surmodics Pharmaceuticals Inc METHOD FOR PRODUCING MICROPARTICLES WITH BIOACTIVE PEPTIDES
SMT202000405T1 (it) * 2008-09-04 2020-09-10 Amylin Pharmaceuticals Llc Formulazioni a rilascio prolungato usando veicolanti non acquosi
US8822610B2 (en) * 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) * 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011084458A2 (en) * 2009-12-15 2011-07-14 The Johns Hopkins University Polymer-based compositions and methods for treatment of peritoneal disorders
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
JP6294885B2 (ja) 2012-08-30 2018-03-14 エーティーアールピー ソリューションズ インコーポレイテッドＡＴＲＰ Ｓｏｌｕｔｉｏｎｓ，Ｉｎｃ． 星形高分子、星形高分子組成物および星形高分子の製造方法
EP2951220B1 (en) 2013-02-04 2020-11-25 Pilot Polymer Technologies, Inc. Salt-tolerant star macromolecules
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015168143A1 (en) * 2014-04-28 2015-11-05 The Johns Hopkins University Biopolymer-encapsulated glycosyltransferase inhibitor compositions and methods for treating diabetes and cardiac indications
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
EP3164429A4 (en) 2014-07-03 2017-12-20 ATRP Solutions, Inc. Surfactant-compatible star macromolecules
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
WO2020232005A1 (en) * 2019-05-13 2020-11-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polymer-based implant for retinal therapy and methods of making and using the same
CN112495319B (zh) * 2020-09-29 2023-07-04 海丰生物科技（北京）有限公司 一种环瓜氨酸肽双微球偶联物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757128A (en) * 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
CH671402A5 (enExample) * 1985-10-02 1989-08-31 Sandoz Ag
US4789724A (en) * 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
WO1995003356A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
AU1702395A (en) * 1994-02-17 1995-09-04 Pankaj Modi Drugs, vaccines and hormones in polylactide coated microspheres
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
JP2000143538A (ja) * 1998-11-04 2000-05-23 Teijin Ltd 免疫調節剤を含有する医薬組成物

Also Published As

Publication number Publication date
JP2004538347A (ja) 2004-12-24
ATE478656T1 (de) 2010-09-15
AU2002322289A1 (en) 2003-01-08
EP1406593B1 (en) 2010-08-25
US20030086895A1 (en) 2003-05-08
WO2003000237A3 (en) 2003-03-27
WO2003000237A2 (en) 2003-01-03
EP1406593A2 (en) 2004-04-14
WO2003000237A8 (en) 2004-12-23
JP4758607B2 (ja) 2011-08-31
US7163697B2 (en) 2007-01-16

Similar Documents

Publication Publication Date Title
ATE478656T1 (de) Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen
WO2006063249A3 (en) Functionalized poly (ether-anhydride) block copolymers
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
MY129356A (en) Electrospun pharmaceutical compositions
BR0107874A (pt) Implante farmacêutico para controlavelmente liberar uma droga, método para controlavelmente liberar uma droga em um indivìduo, e, método para preparar o implante
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
AU2003304237A1 (en) Gel-stabilized nanoparticulate active agent compositions
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
DE60230632D1 (de) Pharmazeutische kombinationen von oxycodon und naloxon
ATE264114T1 (de) Zyklodexrinpolymere zum gebrauch als medikamententräger
ES2118251T3 (es) Preparaciones de microparticulas a base de copolimeros biologicamente degradables.
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
ATE522200T1 (de) Aripiprazole injektionsuspension
TR200102977T2 (tr) Yeni tedavi yöntemi.
UA90077C2 (uk) Антидисритмічні агенти для лікування тазового болю, що призначаються вагінально
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
NO942396L (no) Preparat med vedvarende frigiving av anti-endotelin substans
GEP20063869B (en) Novel cyclohexyl sulphones
AR034372A1 (es) Composiciones farmaceuticas
DK1227797T3 (da) Farmaceutiske faststofdispersionsformuleringer
ATE236616T1 (de) Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten
SE0001916D0 (sv) Novel formulation
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
BR0010699A (pt) Benzimidazóis substituìdos, sua produção e utilização dos mesmos como agente contra protozoários parasitários